UK-based Actimed Therapeutics has regained full global rights to S-oxprenolol (ACM-002) from Faraday Pharmaceuticals, unwinding a 2021 licensing agreement worth up to USD 123.5 million in milestones and restoring control of the muscle-wasting therapy across all indications.
The original 2021 license granted Faraday global rights to develop and commercialize S-oxprenolol in cancer cachexia and all indications except ALS, in exchange for a combined cash and equity upfront of USD 550,000, a near-term milestone of USD 2.7 million, and up to USD 123.5 million in total potential milestones plus royalties.
No public development milestones or clinical updates relating to S-oxprenolol have been disclosed since the agreement was signed. During that period, Faraday advanced its own cachexia candidate, FDY-8801, into Phase II, suggesting its internal program became the company's principal focus.